The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 1×
“A marked impairment is well documented in patients with type 1 diabetes [37] and those with long-standing type 2 diabetes [38], although the degree of impairment in patients with ‘mild’ type 2 diabetes is controversial [39], as are the relative contributions of altered pancreatic glucose sensing and autonomic failure…”
BackgroundNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Reprinted from [93] with kind permission of Springer Science and Business Media 1708”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837 · cited 1×
“The glucagon response to the stimulatory effect of arginine is higher in patients with type 2 diabetes than in nondiabetic subjects [36].”
BackgroundNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationGerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626 · cited 2×
“[34] or a high carbohydrate meal [18] is considerably less”
BackgroundNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“[6, 43, 44].”
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Mitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 1×
“8 mmol/l [3] and decreases progressively as plasma glucose rises above the normal range [4].”
BackgroundKolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 3×
“half-maximal suppression of the AGRarg is substantially higher in diabetic subjects than in normal, glucose-tolerant subjects, suggesting that the sensitivity of the alpha cell to the suppressive effects of glucose is decreased [29].”
BackgroundInfluentialIMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MAN
YALOW, R. S., & BERSON, S. A. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00274.x · Cited by 460
Incretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 1×
“Treatment with liraglutide reduced glucagon levels relative to placebo (by ∼17%) during a hyperglycaemic (15 mmol/l) clamp, and the glucagon AUC during an arginine stimulation test performed during the hyperglycaemic clamp was also reduced (by ∼16%) [103].”
BackgroundØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“In studies examining the effects of GLP-1 infusion during a standardised mixed meal, GLP-1 markedly [77] or completely [78–80] suppressed the meal-induced increase in glucagon and essentially abolished prandial glucose excursions.”
BackgroundMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Gerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353
Creutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*
Unger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104357 · Cited by 285
Glucagon-stimulating activity of 20 amino acids in dogs
Rocha, D. M., Faloona, G. R., & Unger, R. H. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107046 · Cited by 267
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264
Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., Han, J., Taylor, K., Fineman, M., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2397 · Cited by 254
Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide
Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kono, N., & Tarui, S. (1989) · Diabetes · doi:10.2337/diab.38.7.902 · Cited by 234
Harder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 232
Gerich, J. E., Charles, M. A., & Grodsky, G. M. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107823 · Cited by 230
GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes
Ahrén, B., & Schmitz, O. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826178 · Cited by 224
Self-citationRitzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Taborsky, G. J., Ahrén, B., & Havel, P. J. (1998) · Diabetes · doi:10.2337/diabetes.47.7.995 · Cited by 209
Self-citationChang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A., & Halter, J. B. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1786 · Cited by 207
Hartung, R. (1987) · Toxic Substances and Human Risk · doi:10.1007/978-1-4684-5290-7_3 · Cited by 175
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 173
Calcium oscillations and morphological transformations in single cultured gastric parietal cells
Ljungstrom, M., & Chew, C. S. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.260.1.c67 · Cited by 172
Stimulation of Glucagon Secretion by Epinephrine in Man
GERICH, J. E., KARAM, J. H., & FORSHAM, P. H. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-3-479 · Cited by 164
Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 147
Pospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 146
Åhrén, B., Larsson, H., & Holst, J. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3728 · Cited by 145
Gutniak, M., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139
Åhrén, B., Veith, R. C., & Taborsky, G. J. (1987) · Endocrinology · doi:10.1210/endo-121-1-323 · Cited by 138
The Vascular Order of Islet Cellular Perfusion in the Human Pancreas
Stagner, J. I., & Samols, E. (1992) · Diabetes · doi:10.2337/diab.41.1.93 · Cited by 133
The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
Flint, A., Raben, A., Rehfeld, J. F., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 131
The Mechanism of Vagal Nerve Stimulation of Glucagon and Insulin Secretion in the Dog*
Åhrén, B., & Taborsky, G. J. (1986) · Endocrinology · doi:10.1210/endo-118-4-1551 · Cited by 121
Ding, W., Renström, E., Rorsman, P., Buschard, K., & Gromada, J. (1997) · Diabetes · doi:10.2337/diab.46.5.792 · Cited by 120
D’Alessio, D. A., Vogel, R., Prigeon, R. L., Laschansky, E. C., Koerker, D. J., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 119
Nauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113
Suzuki, S., Kawai, K., Ohashi, S., Mukai, H., & Yamashita, K. (1989) · Endocrinology · doi:10.1210/endo-125-6-3109 · Cited by 110
Bolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108 · cited 1×
“A marked impairment is well documented in patients with type 1 diabetes [37] and those with long-standing type 2 diabetes [38], although the degree of impairment in patients with ‘mild’ type 2 diabetes is controversial [39], as are the relative contributions of altered pancreatic glucose sensing and autonomic failure…”
BackgroundIntra-islet insulin permits glucose to directly suppress pancreatic A cell function.
Greenbaum, C. J., Havel, P. J., Taborsky, G. J., & Klaff, L. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115375 · Cited by 106 · cited 1×
“Thus, alpha cells are exposed to very high concentrations of insulin and somatostatin, and there is some evidence to suggest that insulin mediates glucose inhibition of glucagon secretion [13] and that withdrawal of this local insulin ‘tone’ mediates the effect of hypoglycaemia on glucagon release [14].”
BackgroundChideckel, E. W., Palmer, J. P., Koerker, D. J., Ensinck, J. W., Davidson, M. B., & Goodner, C. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107986 · Cited by 103
Meneilly, G., Greig, N., Tildesley, H., Habener, J., Egan, J., & Elahi, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2835 · Cited by 103
Kawai, K., Suzuki, S., Ohashi, S., Mukai, H., Ohmori, H., Murayama, Y., & Yamashita, K. (1989) · Endocrinology · doi:10.1210/endo-124-4-1768 · Cited by 100
Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia
DeFronzo, R. A., Binder, C., Wahren, J., Felig, P., Ferrannini, E., & FABER, O. K. (1981) · European Journal of Endocrinology · doi:10.1530/acta.0.0980081 · Cited by 98
Larsson, H. E., & Åhrén, B. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.650 · Cited by 98
RUSHAKOFF, R. J., GOLDFINE, I. D., CARTER, J. D., & LIDDLE, R. A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-395 · Cited by 96
Ahr�n, B., & Larsson, H. (2001) · Diabetologia · doi:10.1007/s001250100003 · Cited by 95 · cited 1×
“[6, 43, 44].”
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
Behme, M. T., Dupré, J., & McDonald, T. J. (2003) · BMC Endocrine Disorders · doi:10.1186/1472-6823-3-3 · Cited by 93
Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus
Todd, J. F., Wilding, J. P. H., Edwards, C. M. B., KHAN, F. A., Ghatei, M. A., & Bloom, S. R. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.1490691.x · Cited by 93
Filipsson, K., Tornøe, K., Holst, J., & Ahrén, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4230 · Cited by 91
Havel, P. J., & Åhrén, B. (1997) · Diabetes · doi:10.2337/diab.46.5.801 · Cited by 90
Ribel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 84
GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions
Gutniak, M., Larsson, H., Sanders, S. W., Juneskans, O. T., Holst, J. J., & Åhrén, B. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1874 · Cited by 84
Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide
Heller, R. S., & Aponte, G. W. (1995) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1995.269.6.g852 · Cited by 76
Relationship of Islet Function to Insulin Action in Human Obesity*
BEARD, J. C., WARD, W. K., WALLUM, B. J., & PORTE, D. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-59 · Cited by 75
Knigge, U., Holst, J. J., Knuhtsen, S., Petersen, B., Krarup, T., HOLST-PEDERSEN, J., & Christiansen, P. M. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-2-310 · Cited by 75
Gerich, J. E., Tsalikian, E., Lorenzi, M., Schneider, V. B., Bohannon, N. V., Gustafson, G. M., & Karam, J. H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-6-1178 · Cited by 74
Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72 · cited 1×
“In studies examining the effects of GLP-1 infusion during a standardised mixed meal, GLP-1 markedly [77] or completely [78–80] suppressed the meal-induced increase in glucagon and essentially abolished prandial glucose excursions.”
BackgroundGerich, J. E., Langlois, M., Noacco, C., Lorenzi, M., Karam, J. H., & Korsham, P. H. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108475 · Cited by 71
Fridolf, T., Böttcher, G., Sundler, F., & Ahrén, B. (1991) · Pancreas · doi:10.1097/00006676-199103000-00013 · Cited by 69
Self-citationGlucagon immunoreactivity in plasma from normal and dystrophic mice
Ahr�n, B., & Lundquist, I. (1982) · Diabetologia · doi:10.1007/bf00281302 · Cited by 68
Self-citationFehmann, H. C., Hering, B. J., Wolf, M.-J., Brandhorst, H., Brandhorst, D., Bretzel, R. G., Federlin, K., & Göke, B. (1995) · Pancreas · doi:10.1097/00006676-199508000-00014 · Cited by 67
Larsson, H. E., & Åhrén, B. (2000) · Diabetologia · doi:10.1007/s001250050029 · Cited by 65
Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 64
Glucagon-like peptide-1 (7–36 amide): a potent glucagonostatic and insulinotropic hormone
Matsuyama, T., Komatsu, R., Namba, M., Watanabe, N., Itoh, H., & Tarui, S. (1988) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(88)80063-9 · Cited by 64
Suppressive effect of secretin upon pancreatic alpha cell function
Santeusanio, F., Faloona, G. R., & Unger, R. H. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106975 · Cited by 62
Actions of neurohypophysial peptides on pancreatic hormone release
Dunning, B. E., Moltz, J. H., & Fawcett, C. P. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.246.1.e108 · Cited by 60
Self-citationAbnormal Response of Pancreatic Glucagon to Glycemic Changes in Diabetes Mellitus
OHNEDA, A., WANTANABE, K., HORIGOME, K., SAKAI, T., KAI, Y., & OIKAWA, S.-I. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-3-504 · Cited by 49 · cited 2×
“[34] or a high carbohydrate meal [18] is considerably less”
BackgroundMETABOLIC AND HORMONAL RESPONSES TO EXOGENOUS HYPERTHERMIA IN MAN
Møller, N., BECKWITH, R., Butler, P. C., Christensen, N. J., Ørskov, H., & Alberti, K. G. M. M. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00271.x · Cited by 49
Evidence of a paracrine role for pancreatic somatostatin in vivo
Taborsky, G. J. (1983) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1983.245.6.e598 · Cited by 46
Heller, S. R., Macdonald, I. A., & Tattersall, R. B. (1987) · Diabetologia · doi:10.1007/bf00295875 · Cited by 43
Havel, P. J., Parry, S. J., Stern, J. S., Akpan, J. O., Gingerich, R. L., Taborsky, G. J., & CURRY, D. L. (1994) · Metabolism · doi:10.1016/0026-0495(94)90267-4 · Cited by 40
Glucose Modulation of Insulin and Glucagon Secretion in Nondiabetic and Diabetic Man
Hollander, P., Asplin, C. M., & Palmer, J. P. (1982) · Diabetes · doi:10.2337/diab.31.6.489 · Cited by 38
Ikeda, T., Yoshida, T., Ito, Y., Murakami, I., Mokuda, O., Tominaga, M., & Mashiba, H. (1987) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(87)90552-2 · Cited by 36
Silvestre, R. A., Rodríguez‐Gallardo, J., Egido, E. M., & Marco, J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01692-3 · Cited by 35
Hamaguchi, T., Fukushima, H., Uehara, M., Wada, S., Shirotani, T., Kishikawa, H., Ichinose, K., Yamaguchi, K., & Shichiri, M. (1991) · Diabetologia · doi:10.1007/bf00408354 · Cited by 35
Fahrenkrug, J., Pedersen, J., Yamashita, Y., Ottesen, B., Hökfelt, T., & Lundberg, J. (1987) · Regulatory Peptides · doi:10.1016/0167-0115(87)90050-4 · Cited by 34
Yamato, E., Noma, Y., Tahara, Y., Ikegami, H., Yamamoto, Y., Cha, T., Yoneda, H., Ogihara, T., Ohboshi, C., Hirota, M., et al. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92041-w · Cited by 34
Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes
Zander, M., Christiansen, A. L., Madsbad, S., & Holst, J. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1910 · Cited by 32
Ward, F., LEBLANC, H., & YEN, S. S. C. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-3-527 · Cited by 32
Aronoff, S. L., Bennett, P. H., & Unger, R. H. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-44-5-968 · Cited by 30
Gutniak, M., Svartberg, J. B., Hellström, P. M., Holst, J. J., Adner, N., & Åhrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27
Ohneda, A., Ohneda, K., Ohneda, M., Koizumi, F., Ohashi, S., Kawai, K., & Suzuki, S. (1991) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.165.209 · Cited by 24
Matsumura, T., Itoh, H., Watanabe, N., Oda, Y., Tanaka, M., Namba, M., Kôno, N., Matsuyama, T., Komatsu, R., & Matsuzawa, Y. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80836-8 · Cited by 23
Effects of glucagon-like peptide-I on glucose turnover in rats
van Dijk, G., LINDSKOG, S., Holst, J. J., Steffens, A. B., & Åhrén, B. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.6.e1015 · Cited by 22
The Postprandial State: Mechanisms of Glucose Intolerance
Dinneen, S. F. (1997) · Diabetic Medicine · Cited by 22
Guenifi, A., Ahr�n, B., & Abdel‐Halim, S. M. (2001) · Pancreas · doi:10.1097/00006676-200101000-00010 · Cited by 17
Self-citationDifferential effect of isoproterenol on acute glucagon and insulin release in man
Palmer, J. P., Halter, J. B., & Werner, P. L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90069-6 · Cited by 15
Hyperglucagonemia and alpha-adrenergic receptor in acute hypoxia.
Baum, D., Porte, D., & Ensinck, J. W. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.5.e404 · Cited by 12
Responses of the pancreatic A cell during hypoglycemia and hyperglycemia are dependent on the B cell
McCulloch, D. K., Raghu, P., Koerker, D. J., Palmer, J. P., & Klaff, L. J. (1989) · Metabolism · doi:10.1016/0026-0495(89)90111-x · Cited by 11
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Metadata
- Authors
- Dunning, B. E., Foley, J. E., & Ahrén, B.
- Venue
- Diabetologia
- Published
- 2005-08-13
- Volume
- 48
- Issue
- 9
- Pages
- 1700-1713
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1987027636
- Cited by
- 271
- References
- 124
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.